Monthly Archives: February 2021
CIGARETTE SMOKE INCREASES RISK FOR COLORECTAL NEOPLASIA IN INFLAMMATORY BOWEL DISEASE
Patients with inflammatory bowel disease are at increased risk of colorectal neoplasia (CRN) due to mucosal inflammation. As current surveillance guidelines form a burden on patients and healthcare costs, stratification of high-risk patients is crucial… Continue reading
A POPULATION-BASED APPROACH TO DIGITAL OUTREACH, TRIAGE, AND MONITORING OF IBD PATIENTS DURING THE COVID-19 PANDEMIC
In March 2020, the Mount Sinai Health System Inflammatory Bowel Disease (IBD) center reported an increase in telephone call volume, with many IBD patients expressing anxiety about being on immunosuppressive agents during the COVID-19 pandemic. Consiste… Continue reading
COLORECTAL ADENOCARCINOMA DEVELOPING IN A YOUNG FEMALE WITH OVERLAP SYNDROME AND VERY EARLY ONSET-INFLAMMATORY BOWEL DISEASE: A CASE REPORT
We present a 4-year-old female diagnosed with very-early onset inflammatory bowel disease (VEO-IBD), ulcerative colitis type, and overlap syndrome based on clinical presentation, blood and stool studies, diagnostic endoscopies and liver biopsy. Her cli… Continue reading
KAPOSI SARCOMA IN AN IMMUNOSUPPRESSED PATIENT WITH PRESUMED CROHN’S DISEASE: IATROGENIC OR EPIDEMIC?
Biologic immunosuppression and HIV infection both carry risks of infection and malignancy. Small series suggest that patients living with well-controlled HIV may safely and efficaciously use biologics, like TNF-alpha inhibitors (TNF-I). However, no cur… Continue reading
IMMATURE LOW-DENSITY NEUTROPHILS AS MEDIATORS OF PYODERMA GANGRENOSUM AND INFLAMMATORY BOWEL DISEASE PATHOGENESIS
Pyoderma gangrenosum (PG) is a debilitating skin condition characterized by deep, pus-filled, non-healing ulcers packed with neutrophils and is a common extraintestinal manifestation of inflammatory bowel disease (IBD). Strikingly, ∼40% of people with … Continue reading
LOW DOSE IL-2 FOR THE TREATMENT OF MODERATE TO SEVERE ULCERATIVE COLITIS
A significant proportion of patients with ulcerative colitis (UC) have suboptimal responses to medical therapy. Expansion of regulatory T cells (Tregs), but not conventional T cells (Tcons), through the use of low doses (LD) of the T cell growth factor… Continue reading
IS ILEOANAL POUCH EXCISION A DESTINATION THERAPY FOR INFLAMMATORY BOWEL DISEASE? DATA FROM A QUATERNARY POUCH REFERRAL CENTER
Although ileal pouch-anal anastomosis (IPAA) is the surgical procedure of choice of many patients with ulcerative colitis and other conditions, some patients may require pouch excision (PE). We aimed to describe our experience with pouch excisions and … Continue reading
STOCHASTIC INTERINDIVIDUAL MICROBIOME VARIATION MAY GUIDE PROTECTIVE PERINATAL PROBIOTIC DEVELOPMENT AGAINST IBD
The purpose of our experiment was to explore how stochastic inter-individual variation in the mammalian gut microbiome may link to inflammatory bowel disease (IBD) susceptibility, and guide the development of a perinatal preventative probiotic. Continue reading
AN AUTOPHAGY PROTEIN ATG16L1 PREVENTS NECROPTOSIS BY REGULATING INTERFERON SIGNALING IN THE INTESTINAL EPITHELIUM
ATG16L1, an essential component of autophagy, is one of the susceptibility genes of Crohn’s disease. We previously showed mice with decreased expression of Atg16L1 and Crohn’s disease patients homozygous for ATG16L1T300A risk alleles develop Paneth cel… Continue reading
EFFICACY OF INFLIXIMAB DOSE ESCALATION IN PATIENTS WITH REFRACTORY IMMUNOTHERAPY-RELATED COLITIS: A CASE SERIES
Immune checkpoint inhibitor (ICI)-related colitis (irColitis) is a frequent complication of ICI use in cancer. Treatment algorithms have been adapted from the treatment of inflammatory bowel disease (IBD), including the use of infliximab (IFX) for pati… Continue reading